Browse News
Filter News
Found 743 articles
-
Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer
4/11/2024
Candel Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to CAN-2409, Candel’s most advanced multimodal biological immunotherapy candidate, for the treatment of pancreatic cancer.
-
With the American Association for Cancer Research’s annual conference well underway, data from vaccines and other products targeting tough-to-treat cancers have dominated the program.
-
Diakonos Oncology’s Unique Dendritic Cell Vaccine (DOC1021) Improves Survival Compared to Standard of Care in Phase 1 Trial for Glioblastoma
4/9/2024
Diakonos Oncology Corp., a clinical-stage immuno-oncology company, announced today an interim analysis of the Phase 1 open label trial of DOC1021 showing substantially increased survival of glioblastoma multiforme
-
GenFleet Therapeutics Announces Potent Anti-tumor Efficacy of GFH375, an Oral KRAS G12D (ON/OFF) Inhibitor, and its Potential in Combination Therapy with RAF/MEK Clamp at 2024 AACR Annual Meeting
4/9/2024
GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today unveiled the latest research findings of GFH375, an oral KRAS G12D (ON/OFF) inhibitor, at the poster presentation of the 2024 American Association for Cancer Research (AACR) Annual Meeting.
-
Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual Meeting
4/9/2024
Qualigen Therapeutics, Inc. (“Qualigen” or the “Company,” Nasdaq: QLGN) today announces that a poster featuring its early clinical experience with a novel first-in-class G-Quadruplex experimental anti-cancer drug, QN-302, was presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 held April 5 – 10 in San Diego, California.
-
Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors
4/9/2024
Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the presentation of a poster during the American Association for Cancer Research (AACR) Annual Meeting, taking place April 5 through 10 in San Diego.
-
Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
4/8/2024
Revolution Medicines, Inc., a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, announced the publication of two peer-reviewed research papers in Nature.
-
Theriva™ Biologics Announces Presentation at the American Society for Cell and Gene Therapy 27th Annual Meeting
4/8/2024
Theriva™ Biologics today announced the presentation of preclinical data demonstrating the potential synergy between lead product candidate, VCN-01 and liposomal irinotecan in a human pancreatic mouse xenograft.
-
Cantargia presents unique effects of nadunolimab in pancreatic cancer
4/8/2024
Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today presented new preclinical data for its lead candidate, the IL1RAP-binding antibody nadunolimab (CAN04) at the AACR Annual Meeting.
-
Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer
4/7/2024
BioNTech SE announced three-year follow-up data from a Phase 1 trial with the mRNA-based individualized neoantigen-specific immunotherapy candidate autogene cevumeran in patients with resected pancreatic ductal adenocarcinoma.
-
BOLD-100 and ATR Inhibitors as a New Avenue for PDAC Targeting at AACR 2024
4/5/2024
Bold Therapeutics has announced that Dr. Do- Youn Oh's group at Seoul National University College of Medicine, Seoul, South Korea, will be presenting at the AACR Annual Meeting, April 5-10, 2024.
-
Elicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual Meeting
4/5/2024
Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”) today announced that it will be sharing pipeline updates for all investigational candidates at the upcoming American Association for Cancer Research (“AACR”) Annual Meeting, taking place in San Diego, California from April 5-10, 2024.
-
Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
4/4/2024
Candel Therapeutics, Inc. today announced updated interim survival data from the ongoing randomized phase 2 clinical trial of CAN-2409 plus valacyclovir (prodrug), together with standard of care (SoC) chemoradiation, followed by resection for borderline resectable pancreatic ductal adenocarcinoma (PDAC).
-
Vaccinex Reports 2023 Financial Results and Provides Corporate Update
4/2/2024
Vaccinex, Inc. today announced financial results for the fourth quarter ended December 31, 2023 and provided a corporate update on key programs.
-
BostonGene Announces Acceptance of Eight Abstracts to be Presented at the American Association for Cancer Research Annual Meeting 2024
4/2/2024
BostonGene to Present Cutting-Edge Research on Genomic and Transcriptomic Analysis for Cancer Patients.
-
Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
4/1/2024
Biomea Fusion, Inc. reported fourth quarter and full year 2023 financial results and corporate highlights.
-
GeneCentric Therapeutics Announces Upcoming Presentations at the American Association for Cancer Research Annual Meeting 2024
4/1/2024
GeneCentric Therapeutics today announced upcoming presentations at the American Association for Cancer Research Annual Meeting 2024 being held in San Diego, California from April 5-10.
-
Jacobio Pharma Announces 2023 Annual Results
3/29/2024
Pharma (1167.HK), a clinical-stage oncology company drugging the undruggable targets, today announced its 2023 annual results.
-
Elicio Therapeutics Reports 2023 Financial Results and Provides Corporate Updates
3/29/2024
Elicio Therapeutics, Inc. (Nasdaq: ELTX,“Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today reported financial results for the year ending December 31, 2023, and provided recent business highlights.
-
Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024
3/28/2024
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the company will deliver multiple presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024 being held April 5-10, 2024, in San Diego, California.